Prominence of Scientific and company Advisory Board signals attraction to xCures’ novel patient-centric approach to treatment and continuous learning for cancer
LOS ALTOS, CA, USA, October 10, 2019 — Today, xCures Inc. announced the appointment of members to its Scientific Advisory Board (SAB) and company Advisory Board. The SAB supports the work of xCures’ Virtual Tumor Boards in running patient-centered Perpetual Clinical Trials for oncology. xCures currently manages XCELSIOR, a Perpetual Trial collecting real-world data and patient-reported outcomes integrated with AI- and expert-supported Virtual Tumor Boards.
The company Advisory Board provides guidance to the company on technology and business issues. By implementing this precision oncology approach to the treatment of all cancer patients, on all therapies, all the time, xCures aims to develop deep insights into rapid improvements in the treatment of cancer patients.